The EBAG9 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte line, featuring targeted disruption of the EBAG9 gene. This polyclonal pool provides a heterogeneous loss-of-function model, enabling robust assessment of EBAG9-dependent phenotypes without clonal selection artifacts. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, generating a stable population suitable for a wide range of functional studies in immune cell biology and cancer immunology. Researchers can leverage this model to explore the molecular underpinnings of tumor immune evasion and estrogen-modulated apoptosis.
Jurkat cells, originally isolated from the peripheral blood of a 14-year-old male with acute T cell leukemia, serve as a widely utilized model for T cell signaling, apoptosis, and cytokine production. This well-characterized human T lymphocyte line retains key components of T cell receptor signaling pathways and undergoes classical apoptotic responses upon stimulation, making it an ideal host for investigating immune regulatory mechanisms. The immortalized nature of Jurkat cells facilitates genetic manipulation and high-throughput screening, while their leukemic origin provides context for studying oncogenic processes. In conjunction with EBAG9 disruption, these cells become a powerful tool for dissecting gene functions in a T cell milieu relevant to both hematological malignancies and immune surveillance.
EBAG9 encodes a secreted ligand that, upon binding to a putative receptor on immune cells such as T lymphocytes and natural killer cells, triggers apoptosis primarily through the mitochondrial pathway, involving cytochrome c release and caspase-3 activation. Upstream, EBAG9 expression is regulated by estrogen receptor alpha and STAT3 in response to inflammatory cytokines, forming a link between hormonal signaling and immune suppression. The protein product interacts with 14-3-3 proteins and estrogen receptor alpha, facilitating its secretion and functional activity. Downstream, EBAG9-induced apoptosis is modulated by Bcl-2 family proteins, positioning EBAG9 at a critical junction of immune evasion, hormone signaling, and cell death pathways. This signaling network underscores its role in promoting tumor escape by eliminating cytotoxic immune effectors.
In Jurkat T cells, which naturally express functional apoptotic machinery and are responsive to extrinsic death signals, EBAG9 knockout provides a unique platform to dissect how this gene influences T cell survival, activation, and effector functions. Given Jurkat??s origin from T cell leukemia, the model is particularly relevant for studying how leukemia cells might exploit EBAG9 to evade immune-mediated killing. By disrupting EBAG9, researchers can interrogate changes in susceptibility to apoptosis induction, alterations in estrogen-driven proliferation, and modifications in the secretory profile that affect neighboring immune cells. The model thus bridges basic T cell biology with translational cancer research, offering insights into therapeutic strategies targeting immune checkpoint-like mechanisms.
This knockout polyclonal population is ideally suited for a diverse set of experimental applications, including cancer immunology, tumor immune evasion studies, apoptosis mechanism elucidation, and estrogen signaling in immune escape. Representative assays include flow cytometry for Annexin V/7-AAD apoptosis quantification, Western blotting for cleaved caspase-3 and cytochrome c release, RT-qPCR for EBAG9 transcript isoform analysis, co-culture killing assays with effector cells, and estrogen response element reporter assays to monitor hormonal crosstalk. Additionally, immunofluorescence can be used to assess subcellular localization changes of interacting partners. For further technical details and batch-specific validation data, please contact Ascent Research.
